Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research, led by the ...

Booster vaccines reduced the risk of COVID‑19–related hospitalisation and death, according to a new study of over 3 million adults who had the autumn ...

Darkseid Steals Booster Gold's Body! #shorts #boostergold #dccomics #dcuniverse ...

The biotech company said the FDA won’t review its flu vaccine, in the latest hit to mRNA development.

When researchers compared childbirths and miscarriages between vaccinated and unvaccinated women, they found no statistically ...

The National Academy of Engineering has elected Anne Aunins, a University of Virginia chemical engineering alumna and board member of the University of Virginia Engineering Foundation, to its Class of ...

Integration and automation leader achieves 50% customer growth in just over three years Company now serves 30,000+ customers worldwide, including more than a quarter of the Fortune 500 Boomi powers ...

Moderna (NASDAQ:MRNA) executives highlighted progress on cost reductions, a ramp in international partnerships, and multiple late-stage pipeline milestones during the company’s fourth-quarter 2025 ...

Moderna's stock, down 91% from its peak, jumped 16% on positive Phase 2b results for its mRNA skin cancer vaccine, showing a 49% reduction in recurrence. This cancer vaccine is vital for Moderna to ...

Q4 2025 earnings call highlights: revenue, cost cuts, cash outlook, FDA flu setback, and 2026 growth guidance—read key insights now.

The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...

A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial data show the risk of recurrence ...